Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 | CJC-1295 (without DAC / Mod GRF 1-29) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury. | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. |
| Timing | Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing. | Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection. |
| Cycle Duration | Typical cycles range from 4-12 weeks depending on the injury being addressed. | 12-24 week cycles with 4-8 week breaks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.
Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.
Typical cycles range from 4-12 weeks depending on the injury being addressed.
Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.
12-24 week cycles with 4-8 week breaks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →